June 2020
Volume 61, Issue 7
ARVO Annual Meeting Abstract  |   June 2020
Nonpharmaceutical eye wash may reduce Matrix Metalloprotease-9 (MMP-9) in dry eye
Author Affiliations & Notes
  • Alice Kim
    University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Cameron K Postnikoff
    University of Alabama at Birmingham, Birmingham, Alabama, United States
    Coopervision, Pleasanton, California, United States
  • Kelly K Nichols
    University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Footnotes
    Commercial Relationships   Alice Kim, None; Cameron Postnikoff, None; Kelly Nichols, None
  • Footnotes
    Support  The clinical trial was sponsored through an unrestricted research grant from Allergan, plc.
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 100. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alice Kim, Cameron K Postnikoff, Kelly K Nichols; Nonpharmaceutical eye wash may reduce Matrix Metalloprotease-9 (MMP-9) in dry eye. Invest. Ophthalmol. Vis. Sci. 2020;61(7):100.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Past studies have revealed the inflammatory nature of the closed eye environment, and millions of inflammatory mediators are recruited to the ocular surface during sleep. Matrix metalloprotease-9 (MMP-9) has been shown to degrade collagen on the ocular surface when overexpressed. We hypothesize that a nonpharmaceutical eye wash immediately upon awakening may serve as an effective means of reducing MMP-9 on the ocular surface and thus alleviating dry eye symptoms.

Methods : Thirty-six normal and 36 dry eye subjects were randomized and instructed to perform a phosphate buffer saline eye wash and eye wash collection on both eyes immediately upon awakening on two occasions, either daily (treatment) or once every two weeks (control). Supernatants from the eye washes were maintained, and MMP-9 quantification was performed using a Quantikine ELISA (R&D Systems, Minneapolis, MN). MMP-9 concentration was normalized to total protein using a BCA protein assay (ThermoFisher, Waltham, MA). The MMP-9 concentrations of samples were read at 450 nm using a spectrophotometer. Statistical analysis using a two-sample t-test was performed comparing MMP-9 levels at baseline between normal and dry eye groups before and after treatment.

Results : On average, the MMP-9 concentrations decreased from 1.163 to 0.562 ng/mL for the normal group and 0.796 to 0.525 ng/mL for dry eye subjects after treatment. Normalized MMP-9 concentrations at baseline were higher in dry eye subjects. No significant difference was observed between treatment and control subjects at either time point.

Conclusions : These findings demonstrate that MMP-9 concentrations before the eyewash period were higher for dry eye than normal groups. These results are consistent with the hypothesis that MMP-9 may be higher in subjects experiencing dry eye symptoms as compared to normal subjects. Further experiments on related inflammatory mediators are needed to explore the mechanisms of inflammatory dry eye, determine a more easily manageable route of diagnosis and treatment, and determine the effectiveness of a daily eye wash in reducing inflammatory mediators on the ocular surface with consistent use.

This is a 2020 ARVO Annual Meeting abstract.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.